AbbVie Stock Price, News & Analysis (NYSE:ABBV)

$100.34 0.00 (0.00 %)
(As of 01/16/2018 08:30 AM ET)
Previous Close$99.27
Today's RangeN/A
52-Week Range$59.27 - $101.28
Volume197 shs
Average Volume4.47 million shs
Market Capitalization$159.95 billion
P/E Ratio24.35
Dividend Yield2.83%
Beta1.53

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:ABBV
CUSIP00287Y10
Phone+1-847-9327900

Debt

Debt-to-Equity Ratio5.08%
Current Ratio1.45%
Quick Ratio1.32%

Price-To-Earnings

Trailing P/E Ratio24.3543689320388
Forward P/E Ratio18.11
P/E Growth1.2

Sales & Book Value

Annual Sales$25.64 billion
Price / Sales6.25
Cash Flow$5.60 per share
Price / Cash17.93
Book Value$2.85 per share
Price / Book35.21

Profitability

Trailing EPS$4.12
Net Income$5.95 billion
Net Margins24.38%
Return on Equity153.80%
Return on Assets12.83%

Miscellaneous

Employees30,000
Outstanding Shares1,596,430,000

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, October 27th. Stockholders of record on Friday, January 12th will be paid a dividend of $0.71 per share on Thursday, February 15th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie's previous quarterly dividend of $0.64. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has authorized a stock buyback program on Sunday, April 9th 2017, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 5% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board of directors believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, October, 27th. The company reported $1.41 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.39 by $0.02. The firm had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The business's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the firm posted $1.21 EPS. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, January, 26th 2018. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY18 earnings guidance on Friday, October, 27th. The company provided earnings per share (EPS) guidance of $6.37-6.57 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.59. AbbVie also updated its FY17 guidance to $5.53-5.55 EPS.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2018?

14 brokerages have issued twelve-month price targets for AbbVie's shares. Their forecasts range from $84.00 to $120.00. On average, they expect AbbVie's stock price to reach $100.15 in the next twelve months. View Analyst Ratings for AbbVie.

What are Wall Street analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares outperformed the industry in 2017 supported by a series of positive news including promising data from several pivotal studies, regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settlement of its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition. Estimates have remained stable ahead of the Q4 earnings release. AbbVie has a positive record of earnings surprises in the recent quarters." (1/5/2018)
  • 2. UBS Group AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
  • 3. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer (Age 63)
  • William J. Chase, Executive Vice President, Chief Financial Officer (Age 49)
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer (Age 51)
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary (Age 53)
  • Carlos Alban, Executive Vice President - Commercial Operations (Age 54)
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer (Age 44)
  • Timothy J. Richmond, Senior Vice President - Human Resources (Age 50)
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations (Age 53)
  • Robert A. Michael, Vice President, Controller (Age 46)
  • Robert J. Alpern M.D., Independent Director (Age 66)

Who owns AbbVie stock?

AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.03%), Sit Investment Associates Inc. (0.03%), KAMES CAPITAL plc (0.02%), CHURCHILL MANAGEMENT Corp (0.02%), Exxonmobil Investment Management Inc. TX (0.02%) and Pennsylvania Trust Co (0.02%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Exxonmobil Investment Management Inc. TX, Atria Investments LLC, Fulton Bank N.A., Pennsylvania Trust Co, Chesley Taft & Associates LLC, Accurate Investment Solutions Inc., CHURCHILL MANAGEMENT Corp and Gofen & Glossberg LLC IL. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was purchased by a variety of institutional investors in the last quarter, including Broadleaf Partners LLC, Sawyer & Company Inc, Montrusco Bolton Investments Inc., Bristol Advisors LLC, Tandem Investment Advisors Inc., Nisa Investment Advisors LLC, KCS Wealth Advisory and Atalanta Sosnoff Capital LLC. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $100.34.

How big of a company is AbbVie?

AbbVie has a market capitalization of $159.95 billion and generates $25.64 billion in revenue each year. The company earns $5.95 billion in net income (profit) each year or $4.12 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

How can I contact AbbVie?

AbbVie's mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The company can be reached via phone at +1-847-9327900.


MarketBeat Community Rating for AbbVie (ABBV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  647 (Vote Outperform)
Underperform Votes:  388 (Vote Underperform)
Total Votes:  1,035
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AbbVie (NYSE:ABBV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.642.632.54
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $100.15$99.77$93.33$74.58
Price Target Upside: 1.18% upside4.57% upside2.94% upside2.49% upside

AbbVie (NYSE:ABBV) Consensus Price Target History

Price Target History for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2018BMO Capital MarketsSet Price TargetHold$84.00LowView Rating Details
1/4/2018Jefferies GroupBoost Price TargetBuy$115.00 -> $120.00LowView Rating Details
1/2/2018Piper Jaffray CompaniesReiterated RatingBuyHighView Rating Details
12/5/2017Leerink SwannSet Price TargetBuy$106.00LowView Rating Details
11/21/2017Societe GeneraleBoost Price TargetN/AView Rating Details
10/30/2017SunTrust BanksReiterated RatingBuyN/AView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$90.00N/AView Rating Details
10/11/2017CowenUpgradeMarket Perform -> Outperform$91.17 -> $105.00N/AView Rating Details
10/1/2017Credit Suisse GroupReiterated RatingNeutral$74.00 -> $94.00MediumView Rating Details
9/30/2017Evercore ISIReiterated RatingOutperform$95.00 -> $100.00MediumView Rating Details
9/29/2017ArgusBoost Price TargetBuy$90.00 -> $110.00LowView Rating Details
9/29/2017Morgan StanleyBoost Price TargetEqual Weight$70.00 -> $95.00LowView Rating Details
9/28/2017Deutsche BankBoost Price TargetHold$88.00LowView Rating Details
9/8/2017Goldman Sachs GroupReiterated RatingBuy$85.00 -> $100.00LowView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016CitigroupDowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James FinancialInitiated CoverageOutperform$82.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

AbbVie (NYSE:ABBV) Earnings History and Estimates Chart

Earnings by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE ABBV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/26/2018$1.43N/AView Earnings Details
10/27/2017Q3 2017$1.39$1.41$7.00 billion$7.00 billionViewN/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.93 billion$6.94 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AbbVie (NYSE:ABBV) Earnings Estimates

2018 EPS Consensus Estimate: $6.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.56$1.56$1.56
Q2 20181$1.75$1.75$1.75
Q3 20181$1.79$1.79$1.79
Q4 20181$1.89$1.89$1.89
(Earnings estimates data provided by Zacks Investment Research)

Dividends

AbbVie (NYSE:ABBV) Dividend Information

Next Dividend:2/15/2018
Annual Dividend:$2.84
Dividend Yield:2.83%
Dividend Growth:15.50% (3 Year Average)
Payout Ratio:68.93% (Trailing 12 Months of Earnings)
51.26% (Based on This Year's Estimates)
43.83% (Based on Next Year's Estimates)
Track Record:45 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2017Quarterly$0.713.12%1/11/20181/12/20182/15/2018
9/8/2017Quarterly$0.642.94%10/12/201710/13/201711/15/2017
6/23/2017quarterly$0.643.52%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.644.14%4/11/20174/13/20175/15/2017
10/28/2016quarterly$0.644.44%1/11/20171/13/20172/15/2017
9/12/2016quarterly$0.573.56%10/12/201610/14/201611/15/2016
6/17/2016quarterly$0.573.8%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.574.2%4/13/20164/15/20165/16/2016
11/2/2015quarterly$0.573.6%1/13/20161/15/20162/16/2016
9/14/2015quarterly$0.513.46%10/13/201510/15/201511/14/2015
6/19/2015quarterly$0.512.94%7/13/20157/15/20158/14/2015
2/20/2015quarterly$0.513.33%4/13/20154/15/20155/15/2015
10/20/2014quarterly$0.493.48%1/13/20151/15/20152/13/2015
9/19/2014quarterly$0.422.86%10/10/201410/15/201411/17/2014
6/19/2014quarterly$0.423.15%7/11/20147/15/20148/15/2014
2/20/2014quarterly$0.423.29%4/11/20144/15/20145/15/2014
12/12/2013quarterly$0.403.06%1/13/20141/15/20142/14/2014
9/19/2013quarterly$0.403.34%10/10/201310/15/201311/15/2013
6/20/2013quarterly$0.403.75%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.404.19%4/11/20134/15/20135/15/2013
1/7/2013special$0.401/11/20131/15/20132/15/2013
1/4/2013quarterly$0.401/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.19%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Insider Trades by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE ABBV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Timothy J RichmondSVPSell87,040$98.45$8,569,088.00113,118View SEC Filing  
12/15/2017Laura J SchumacherInsiderSell145,510$96.71$14,072,272.10View SEC Filing  
11/21/2017Richard A GonzalezChairmanSell218,193$94.01$20,512,323.93492,030View SEC Filing  
11/10/2017Michael SeverinoEVPSell25,633$94.69$2,427,188.77114,922View SEC Filing  
10/30/2017Henry O GosebruchInsiderSell18,300$90.55$1,657,065.0081,287View SEC Filing  
9/28/2017Robert A MichaelVPSell6,699$88.00$589,512.0010,007View SEC Filing  
9/11/2017Azita Saleki-GerhardtSVPSell8,300$85.02$705,666.0093,099View SEC Filing  
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00469,623View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98342,353View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00342,353View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.0015,498View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.0096,074View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00160,545View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00187,625View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15349,462View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00209,043View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00114,745View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00147,415View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.2816,706View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.7926,078View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00369,113View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00178,970View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00144,138View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18260,438View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46624,374View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00338,421View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76149,444View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.0068,204View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.1644,615View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00199,238View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.3079,064View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80395,403View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.7585,828View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38205,138View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56180,068View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.3266,703View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.7064,279View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.4164,237View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AbbVie (NYSE ABBV) News Headlines

Source:
DateHeadline
Your Daily Pharma Scoop: AbbVie Highlights Pipeline, Novavax Surges, Lipocine Flops At Ad Com - Seeking AlphaYour Daily Pharma Scoop: AbbVie Highlights Pipeline, Novavax Surges, Lipocine Flops At Ad Com - Seeking Alpha
seekingalpha.com - January 13 at 5:11 AM
AbbVie Target of Unusually Large Options Trading (ABBV)AbbVie Target of Unusually Large Options Trading (ABBV)
www.americanbankingnews.com - January 13 at 3:48 AM
AbbVie Inc (ABBV) Receives Average Recommendation of "Buy" from AnalystsAbbVie Inc (ABBV) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 12 at 3:52 PM
Should You Jump on the Marijuana Bandwagon?Should You Jump on the Marijuana Bandwagon?
finance.yahoo.com - January 12 at 3:11 PM
The Arrival of MarijuanaThe Arrival of Marijuana
finance.yahoo.com - January 12 at 3:11 PM
Gauging Marijuana Risk: The Potential Investment BlowbackGauging Marijuana Risk: The Potential Investment Blowback
finance.yahoo.com - January 12 at 3:11 PM
BMO Capital Markets Analysts Give AbbVie (ABBV) a $84.00 Price TargetBMO Capital Markets Analysts Give AbbVie (ABBV) a $84.00 Price Target
www.americanbankingnews.com - January 11 at 3:32 PM
7 Must-See Numbers From AbbVie's J. P. Morgan Presentation7 Must-See Numbers From AbbVie's J. P. Morgan Presentation
finance.yahoo.com - January 11 at 3:15 PM
Earnings Season Watch List: AbbVieEarnings Season Watch List: AbbVie
finance.yahoo.com - January 11 at 3:15 PM
Mavyret May Prove a Strong Growth Driver for AbbVie Going ForwardMavyret May Prove a Strong Growth Driver for AbbVie Going Forward
finance.yahoo.com - January 11 at 3:15 PM
FDA Advisors Slam Lipocines Testosterone Pill, Raising Doubts About Low T DrugsFDA Advisors Slam Lipocine's Testosterone Pill, Raising Doubts About 'Low T' Drugs
finance.yahoo.com - January 11 at 3:15 PM
Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ) - Motley FoolBetter Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ) - Motley Fool
www.fool.com - January 11 at 5:05 AM
AbbVies Upadacitinib Gains Breakthrough Therapy DesignationAbbVie's Upadacitinib Gains Breakthrough Therapy Designation
finance.yahoo.com - January 10 at 3:14 PM
Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ)Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ)
finance.yahoo.com - January 10 at 3:14 PM
Ex-Dividend Alert: AbbVie Raised its Dividend by 11%; Will Trade Ex-Dividend on January 11, 2018Ex-Dividend Alert: AbbVie Raised its Dividend by 11%; Will Trade Ex-Dividend on January 11, 2018
finance.yahoo.com - January 10 at 3:14 PM
Analysts’ Recommendations for Incyte in January 2018Analysts’ Recommendations for Incyte in January 2018
finance.yahoo.com - January 10 at 3:14 PM
AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?
finance.yahoo.com - January 10 at 3:14 PM
Is AbbVie Stock Still A Strong Buy? - Motley FoolIs AbbVie Stock Still A Strong Buy? - Motley Fool
www.fool.com - January 10 at 5:10 AM
Ex-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories - NasdaqEx-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories - Nasdaq
www.nasdaq.com - January 10 at 5:10 AM
AbbVie"s JAK1 Inhibitor Granted FDA"s Breakthrough TherapyAbbVie"s JAK1 Inhibitor Granted FDA"s Breakthrough Therapy
finance.yahoo.com - January 9 at 3:11 PM
4 Best Marijuana Stocks to Play the Green Rush4 Best Marijuana Stocks to Play the Green Rush
finance.yahoo.com - January 9 at 3:11 PM
Is AbbVie Stock Still A Strong Buy? Is AbbVie Stock Still A Strong Buy?
www.fool.com - January 9 at 2:56 PM
Judge allows evidence of plaintiffs prior diseases in AndroGel trial - ReutersJudge allows evidence of plaintiff's prior diseases in AndroGel trial - Reuters
www.reuters.com - January 9 at 5:08 AM
Cramers lightning round: Mercadolibre is even better than eBay was - CNBCCramer's lightning round: Mercadolibre is even better than eBay was - CNBC
www.cnbc.com - January 9 at 5:08 AM
Cramer's lightning round: Mercadolibre is even better tha...Cramer's lightning round: Mercadolibre is even better tha...
finance.yahoo.com - January 9 at 5:08 AM
Cramers lightning round: Mercadolibre is even better than eBay wasCramer's lightning round: Mercadolibre is even better than eBay was
finance.yahoo.com - January 9 at 5:08 AM
Why AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid ArthritisWhy AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
finance.yahoo.com - January 8 at 11:28 AM
Understanding AbbVie’s Positive Upadacitinib Data for Atopic DermatitisUnderstanding AbbVie’s Positive Upadacitinib Data for Atopic Dermatitis
finance.yahoo.com - January 8 at 11:27 AM
AbbVie Inc (ABBV) Increases Dividend to $0.71 Per ShareAbbVie Inc (ABBV) Increases Dividend to $0.71 Per Share
www.americanbankingnews.com - January 6 at 9:00 AM
Top 5 Biotech Stocks for 2018Top 5 Biotech Stocks for 2018
finance.yahoo.com - January 6 at 6:46 AM
AbbVie and Peers: Analyst Recommendations in DecemberAbbVie and Peers: Analyst Recommendations in December
finance.yahoo.com - January 5 at 3:15 PM
Why AbbVie Is Expected to Report Robust Revenue Growth for 2017Why AbbVie Is Expected to Report Robust Revenue Growth for 2017
finance.yahoo.com - January 5 at 3:15 PM
Spiros Segalas Buys 3 New Stocks in 4th QuarterSpiros Segalas Buys 3 New Stocks in 4th Quarter
finance.yahoo.com - January 5 at 3:15 PM
Why AbbVie Could See a Big Rise in Its Net Profit Margin in Fiscal 2017Why AbbVie Could See a Big Rise in Its Net Profit Margin in Fiscal 2017
finance.yahoo.com - January 5 at 3:15 PM
Jefferies Group Analysts Reduce Earnings Estimates for AbbVie Inc (ABBV)Jefferies Group Analysts Reduce Earnings Estimates for AbbVie Inc (ABBV)
www.americanbankingnews.com - January 5 at 2:14 PM
AbbVie (ABBV) Cut to "Hold" at Zacks Investment ResearchAbbVie (ABBV) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 5 at 12:03 PM
Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018? - NasdaqCan AbbVie (ABBV) Stock Keep the Momentum Alive in 2018? - Nasdaq
www.nasdaq.com - January 5 at 5:24 AM
Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?
finance.yahoo.com - January 4 at 3:02 PM
Blizzard Pounds New York, Boston as Bomb Cyclone Cripples East Coast AirportsBlizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports
finance.yahoo.com - January 4 at 3:02 PM
AbbVie (ABBV) Given New $120.00 Price Target at Jefferies GroupAbbVie (ABBV) Given New $120.00 Price Target at Jefferies Group
www.americanbankingnews.com - January 4 at 10:28 AM
FDA advancing plan to streamline generic drug reviews - AbbVie Inc ... - Seeking AlphaFDA advancing plan to streamline generic drug reviews - AbbVie Inc ... - Seeking Alpha
seekingalpha.com - January 4 at 5:06 AM
US drug approvals highest in 21 years - Seeking AlphaUS drug approvals highest in 21 years - Seeking Alpha
seekingalpha.com - January 2 at 3:10 PM
Stocks to watch next week - AbbVie Inc. (NYSE:ABBV) | Seeking Alpha - Seeking AlphaStocks to watch next week - AbbVie Inc. (NYSE:ABBV) | Seeking Alpha - Seeking Alpha
seekingalpha.com - December 31 at 5:04 AM
ValuEngine Lowers AbbVie (ABBV) to BuyValuEngine Lowers AbbVie (ABBV) to Buy
www.americanbankingnews.com - December 30 at 11:18 AM
AbbVie Inc Dividend at Risk Amid Patent Protection Problems ... - Investorplace.comAbbVie Inc Dividend at Risk Amid Patent Protection Problems ... - Investorplace.com
investorplace.com - December 30 at 5:19 AM
AbbVie Inc (ABBV) Expected to Announce Quarterly Sales of $7.56 BillionAbbVie Inc (ABBV) Expected to Announce Quarterly Sales of $7.56 Billion
www.americanbankingnews.com - December 29 at 8:54 PM
ETFs with exposure to AbbVie, Inc. : December 29, 2017ETFs with exposure to AbbVie, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 3:10 PM
AbbVie Inc Dividend at Risk Amid Patent Protection ProblemsAbbVie Inc Dividend at Risk Amid Patent Protection Problems
investorplace.com - December 29 at 6:39 AM
Heres How AbbVie Inc. Crushed It in 2017Here's How AbbVie Inc. Crushed It in 2017
finance.yahoo.com - December 23 at 8:17 PM
AbbVie (ABBV) Upgraded by Vetr to "Strong-Buy"AbbVie (ABBV) Upgraded by Vetr to "Strong-Buy"
www.americanbankingnews.com - December 23 at 6:22 PM

SEC Filings

AbbVie (NYSE:ABBV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AbbVie (NYSE ABBV) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.